Cargando…
Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
BACKGROUND: Chronic kidney disease (CKD) is common and increasing in prevalence. Cardiovascular disease (CVD) is a major cause of morbidity and death in CKD, though of a different phenotype to the general CVD population. Few therapies have proved effective in modifying the increased CVD risk or rate...
Autores principales: | Hill, Nathan R, Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, Hobbs, FD Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4113231/ https://www.ncbi.nlm.nih.gov/pubmed/24886488 http://dx.doi.org/10.1186/1745-6215-15-160 |
Ejemplares similares
-
Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
por: Hill, Nathan R., et al.
Publicado: (2022) -
Understanding tensions and identifying clinician agreement on improvements to early-stage chronic kidney disease monitoring in primary care: a qualitative study
por: Simmonds, Rosemary, et al.
Publicado: (2016) -
What is the value of multidisciplinary care for chronic kidney disease?
por: Fluck, Richard J., et al.
Publicado: (2018) -
Chronic kidney disease: identification and management in primary care
por: Fraser, Simon DS, et al.
Publicado: (2016) -
Incorporating patient-reported symptom assessments into routine care for people with chronic kidney disease
por: van der Veer, Sabine N, et al.
Publicado: (2017)